Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
NCT03023384
·
clinicaltrials.gov ↗
UNKNOWN
Status
547
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Sponsor
International Consortium on Acute Leukemias